Related Experiment Video
Updated: Feb 3, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Atherosclerotic cardiovascular disease risk assessment in familial hypercholesterolemia: does one size fit all?
Pedro Mata1, Rodrigo Alonso1,2, Leopoldo Pérez de Isla1,3
1Fundación Hipercolesterolemia Familiar, Madrid, Spain.
Insights
Familial hypercholesterolemia patients need better risk assessment for atherosclerotic cardiovascular disease (ASCVD). The SAFEHEART risk equation and coronary imaging improve prediction, guiding new lipid-lowering therapies.
Area of Science:
- Cardiovascular Medicine
- Genetics
- Medical Imaging
Background:
- Familial hypercholesterolemia (FH) is a common genetic disorder causing high LDL-cholesterol and early atherosclerotic cardiovascular disease (ASCVD).
- Statins are standard treatment, but novel therapies necessitate improved identification of high-residual-risk FH patients.
- Accurate cardiovascular risk stratification is crucial for optimizing ASCVD prevention in FH.
Purpose of the Study:
- To review recent literature on cardiovascular risk stratification in FH.
- To highlight the role of coronary imaging in assessing ASCVD risk.
- To update on tools for predicting ASCVD in familial hypercholesterolemia.
Main Methods:
- Review of recent scientific literature on FH and ASCVD risk.
- Evaluation of clinical scores, coronary imaging (coronary-CTA), and biomarkers for risk prediction.
- Focus on the SAFEHEART risk-equation (SAFEHEART-RE) for ASCVD risk assessment.
Main Results:
- Clinical scores, coronary imaging, and novel biomarkers are independent predictors of ASCVD in FH.
- The SAFEHEART-RE offers a more accurate prediction of ASCVD in familial hypercholesterolemia.
- Coronary computed-tomographic angiography (coronary-CTA) findings correlate with SAFEHEART-RE risk estimates.
Conclusions:
- The SAFEHEART-RE is a simple, applicable tool for predicting ASCVD in FH patients.
- Coronary-CTA provides valuable information on atherosclerosis burden in FH.
- Integrating SAFEHEART-RE, coronary-CTA, and biomarkers can enhance ASCVD risk stratification and optimize lipid-lowering therapy use in FH.
Purpose Of Review:
Familial hypercholesterolemia is a frequent genetic disease associated with lifelong elevation of LDL-cholesterol and premature atherosclerotic cardiovascular disease (ASCVD). Statins are the cornerstone of treatment. However, with the introduction of novel LDL-cholesterol-lowering therapies, it is necessary to identify familial hypercholesterolemia patients presenting a significantly high residual ASCVD risk. The aim of this review is to provide an update on the recent literature concerning cardiovascular risk stratification including the role of coronary imaging.
Recent Findings:
Several factors have shown to be independent predictors of ASCVD in familial hypercholesterolemia. These include clinical scores with cardiovascular risk factors, coronary imaging and novel protein biomarkers. However, the recent introduction of the SAFEHEART risk-equation (SAFEHEART-RE) could allow a more accurate ASCVD risk prediction in familial hypercholesterolemia.
Summary:
This article highlights the SAFEHEART-RE as a model to predict incident ASCVD in familial hypercholesterolemia. This equation is a simple and widely applicable tool for use in every clinical setting. Furthermore, coronary atherosclerosis assessed by coronary computed-tomographic angiography (coronary-CTA) is independently associated to the cardiovascular risk estimated according to the SAFEHEART-RE. This equation, as well as coronary-CTA and new biomarkers, could increase individual ASCVD risk stratification and could improve the efficiency and the use of new lipid-lowering therapies in familial hypercholesterolemia.
Related Concept Videos
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Protein Families
Gene Families
Occasionally these regions can be adapted to take on new roles within the organism, becoming novel genes...
Gene Families
Assessment of the Cardiovascular System II: Inspection
Head and Neck
Assessment of the Cardiovascular System IV: Auscultation
Normal Heart Sounds
S1 (First Heart Sound)-
S1 is made by the closure of the mitral and tricuspid valves (atrioventricular valves), marking the beginning of systole.
S2 (Second Heart Sound)-
S2 is made by the closure of the aortic and pulmonic valves (semilunar valves), marking the end of the systole.

